DK1802336T3 - Malaria primer/boostervacciner - Google Patents
Malaria primer/boostervaccinerInfo
- Publication number
- DK1802336T3 DK1802336T3 DK05808091.2T DK05808091T DK1802336T3 DK 1802336 T3 DK1802336 T3 DK 1802336T3 DK 05808091 T DK05808091 T DK 05808091T DK 1802336 T3 DK1802336 T3 DK 1802336T3
- Authority
- DK
- Denmark
- Prior art keywords
- malaria
- primer
- booster vaccines
- regimens
- vaccines
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 201000004792 malaria Diseases 0.000 title 1
- 241000223960 Plasmodium falciparum Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229940126583 recombinant protein vaccine Drugs 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61905604P | 2004-10-14 | 2004-10-14 | |
| EP04105035 | 2004-10-14 | ||
| PCT/EP2005/055209 WO2006040334A1 (en) | 2004-10-14 | 2005-10-13 | Malaria prime/boost vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1802336T3 true DK1802336T3 (da) | 2011-11-14 |
Family
ID=34929701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05808091.2T DK1802336T3 (da) | 2004-10-14 | 2005-10-13 | Malaria primer/boostervacciner |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20080131461A1 (da) |
| EP (1) | EP1802336B1 (da) |
| JP (1) | JP5108521B2 (da) |
| KR (1) | KR20070104881A (da) |
| CN (1) | CN101068568B (da) |
| AT (1) | ATE523205T1 (da) |
| AU (1) | AU2005293572B2 (da) |
| BR (1) | BRPI0518146A (da) |
| CA (1) | CA2582455A1 (da) |
| CY (1) | CY1112749T1 (da) |
| DK (1) | DK1802336T3 (da) |
| EA (1) | EA016648B1 (da) |
| ES (1) | ES2371175T3 (da) |
| HK (1) | HK1100121A1 (da) |
| HR (1) | HRP20110786T1 (da) |
| IL (2) | IL182357A0 (da) |
| MA (1) | MA29212B1 (da) |
| MX (1) | MX2007004031A (da) |
| NO (1) | NO20072470L (da) |
| NZ (1) | NZ583291A (da) |
| PL (1) | PL1802336T3 (da) |
| PT (1) | PT1802336E (da) |
| RS (1) | RS52187B (da) |
| SI (1) | SI1802336T1 (da) |
| WO (1) | WO2006040334A1 (da) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI0833934T2 (sl) | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
| US6929946B1 (en) * | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
| US20050164386A1 (en) * | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
| US20050002958A1 (en) * | 1999-06-29 | 2005-01-06 | Smithkline Beecham Biologicals Sa | Vaccines |
| US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
| US7521220B2 (en) * | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| AU2002351444B2 (en) * | 2001-12-07 | 2008-02-21 | Crucell Holland B.V. | Production of viruses, viral isolates and vaccines |
| AU2003298361B2 (en) | 2002-12-17 | 2009-05-14 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| KR101206206B1 (ko) * | 2003-07-22 | 2012-11-29 | 크루셀 홀란드 비.브이. | 사스-코로나바이러스에 대한 결합분자 및 그것의 용도 |
| JP5108521B2 (ja) * | 2004-10-14 | 2012-12-26 | クルセル ホランド ベー ヴェー | マラリア初回免疫／追加免疫ワクチン |
| GB0513421D0 (en) | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
| US20090110695A1 (en) * | 2006-03-27 | 2009-04-30 | Menzo Jans Emko Havenga | Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
| US9717788B2 (en) | 2007-03-02 | 2017-08-01 | Glaxosmithkline Biologicals Sa | Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant |
| KR20100068390A (ko) | 2007-08-13 | 2010-06-23 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| CN101883858B (zh) * | 2007-11-28 | 2015-07-22 | 宾夕法尼亚大学托管会 | 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用 |
| DK2220242T3 (da) * | 2007-11-28 | 2017-03-27 | Univ Pennsylvania | Abe-adenovira af undergruppe b, sadv-28,27,-29,-32,-33 og -35 og anvendelser deraf |
| TW200938633A (en) * | 2007-12-06 | 2009-09-16 | Glaxosmithkline Biolog Sa | Vaccine |
| JP5661476B2 (ja) | 2008-03-04 | 2015-01-28 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途 |
| WO2010040000A2 (en) * | 2008-10-01 | 2010-04-08 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | A multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia |
| CA2742474C (en) * | 2008-11-03 | 2016-05-31 | Crucell Holland B.V. | Method for the production of adenoviral vectors |
| ES2484093T3 (es) | 2009-07-16 | 2014-08-11 | Crucell Holland B.V. | Producción de poliovirus con títulos elevados para producción de vacunas |
| WO2012041669A1 (en) | 2010-09-27 | 2012-04-05 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
| AU2011343798B2 (en) * | 2010-12-14 | 2016-07-14 | Janssen Vaccines & Prevention B.V. | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
| AU2012243039B2 (en) | 2011-04-08 | 2017-07-13 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| NZ628206A (en) | 2012-02-16 | 2016-03-31 | Vlp Therapeutics Llc | Virus like particle composition |
| SG10201609511XA (en) | 2012-05-18 | 2016-12-29 | Univ Pennsylvania | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof |
| JP6734651B2 (ja) | 2013-06-03 | 2020-08-05 | ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ | マラリアワクチン |
| US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
| US9321834B2 (en) | 2013-12-05 | 2016-04-26 | Leidos, Inc. | Anti-malarial compositions |
| GB201405921D0 (en) | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| US10400034B2 (en) | 2014-06-26 | 2019-09-03 | Janssen Vaccines & Prevention, B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| WO2016021209A1 (en) | 2014-08-08 | 2016-02-11 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein e3 |
| KR102532832B1 (ko) | 2014-09-11 | 2023-05-16 | 브이엘피 테라퓨틱스 인코포레이티드 | 플라비바이러스 바이러스 유사 입자 |
| WO2016059911A1 (ja) * | 2014-10-17 | 2016-04-21 | 国立大学法人金沢大学 | マラリアワクチン |
| EP3600399A4 (en) * | 2017-03-30 | 2021-03-24 | The United States of America, as represented by the Secretary of the Navy | METHODS AND COMPOSITIONS FOR VACCINE AGAINST MALARIA |
| US20200397892A1 (en) * | 2018-02-22 | 2020-12-24 | Turnstone Limited Partnership | Oncolytic viruses as adjuvants |
| BR112021009422A2 (pt) * | 2018-12-21 | 2021-10-26 | Curevac Ag | Rna para vacinas contra malária |
| CA3176902A1 (en) | 2020-03-27 | 2021-09-30 | Svenska Vaccinfabriken Produktion Ab | Compositions and methods for treating and preventing coronaviruses |
| WO2023056284A1 (en) | 2021-09-29 | 2023-04-06 | Svenska Vaccinfabriken Produktion Ab | Compositions and methods for treating and preventing coronavirus infection |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6306625B1 (en) * | 1988-12-30 | 2001-10-23 | Smithkline Beecham Biologicals, Sa | Method for obtaining expression of mixed polypeptide particles in yeast |
| SG48390A1 (en) * | 1991-11-16 | 1998-04-17 | Smithkline Beecham Biolog | Hybrid protein between cs from plasmodium and hbs ag |
| FR2763959A1 (fr) * | 1997-06-02 | 1998-12-04 | Transgene Sa | Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage |
| US7604960B2 (en) * | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
| US20050164386A1 (en) * | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
| US7527961B2 (en) * | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
| US7521220B2 (en) * | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
| AU2002351444B2 (en) * | 2001-12-07 | 2008-02-21 | Crucell Holland B.V. | Production of viruses, viral isolates and vaccines |
| EP1553983A2 (en) * | 2002-10-23 | 2005-07-20 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| US20080153083A1 (en) * | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
| US7491395B2 (en) * | 2002-11-20 | 2009-02-17 | Bestewil Holding B.V. | Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination |
| AU2003298361B2 (en) * | 2002-12-17 | 2009-05-14 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| KR101206206B1 (ko) * | 2003-07-22 | 2012-11-29 | 크루셀 홀란드 비.브이. | 사스-코로나바이러스에 대한 결합분자 및 그것의 용도 |
| JP5108521B2 (ja) * | 2004-10-14 | 2012-12-26 | クルセル ホランド ベー ヴェー | マラリア初回免疫／追加免疫ワクチン |
| US8106170B2 (en) * | 2004-11-11 | 2012-01-31 | Crucell Holland B.V. | Compositions against SARS-coronavirus and uses thereof |
-
2005
- 2005-10-13 JP JP2007536175A patent/JP5108521B2/ja not_active Expired - Fee Related
- 2005-10-13 SI SI200531402T patent/SI1802336T1/sl unknown
- 2005-10-13 AU AU2005293572A patent/AU2005293572B2/en not_active Ceased
- 2005-10-13 EP EP05808091A patent/EP1802336B1/en active Active
- 2005-10-13 CN CN2005800348023A patent/CN101068568B/zh not_active Expired - Fee Related
- 2005-10-13 BR BRPI0518146-1A patent/BRPI0518146A/pt not_active IP Right Cessation
- 2005-10-13 DK DK05808091.2T patent/DK1802336T3/da active
- 2005-10-13 RS RS20110493A patent/RS52187B/en unknown
- 2005-10-13 MX MX2007004031A patent/MX2007004031A/es active IP Right Grant
- 2005-10-13 US US11/665,393 patent/US20080131461A1/en not_active Abandoned
- 2005-10-13 ES ES05808091T patent/ES2371175T3/es active Active
- 2005-10-13 PT PT05808091T patent/PT1802336E/pt unknown
- 2005-10-13 WO PCT/EP2005/055209 patent/WO2006040334A1/en active Application Filing
- 2005-10-13 KR KR1020077010360A patent/KR20070104881A/ko not_active Application Discontinuation
- 2005-10-13 EA EA200700849A patent/EA016648B1/ru not_active IP Right Cessation
- 2005-10-13 AT AT05808091T patent/ATE523205T1/de active
- 2005-10-13 PL PL05808091T patent/PL1802336T3/pl unknown
- 2005-10-13 CA CA002582455A patent/CA2582455A1/en not_active Abandoned
- 2005-10-13 NZ NZ583291A patent/NZ583291A/en not_active IP Right Cessation
-
2007
- 2007-04-01 IL IL182357A patent/IL182357A0/en unknown
- 2007-05-14 NO NO20072470A patent/NO20072470L/no not_active Application Discontinuation
- 2007-05-14 MA MA29903A patent/MA29212B1/fr unknown
- 2007-07-25 HK HK07108068.3A patent/HK1100121A1/xx not_active IP Right Cessation
-
2008
- 2008-12-23 US US12/317,508 patent/US20090285879A1/en not_active Abandoned
-
2011
- 2011-08-04 IL IL214460A patent/IL214460A0/en unknown
- 2011-08-23 US US13/199,273 patent/US20120014994A1/en not_active Abandoned
- 2011-10-26 HR HR20110786T patent/HRP20110786T1/hr unknown
- 2011-11-07 CY CY20111101072T patent/CY1112749T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA016648B1 (ru) | 2012-06-29 |
| CN101068568B (zh) | 2012-09-26 |
| HRP20110786T1 (hr) | 2011-12-31 |
| ATE523205T1 (de) | 2011-09-15 |
| MX2007004031A (es) | 2007-11-08 |
| IL214460A0 (en) | 2011-09-27 |
| PT1802336E (pt) | 2011-11-15 |
| CA2582455A1 (en) | 2006-04-20 |
| US20080131461A1 (en) | 2008-06-05 |
| JP2008516926A (ja) | 2008-05-22 |
| KR20070104881A (ko) | 2007-10-29 |
| EP1802336A1 (en) | 2007-07-04 |
| SI1802336T1 (sl) | 2012-01-31 |
| CN101068568A (zh) | 2007-11-07 |
| EA200700849A1 (ru) | 2007-10-26 |
| NZ583291A (en) | 2011-06-30 |
| NO20072470L (no) | 2007-07-16 |
| IL182357A0 (en) | 2007-07-24 |
| US20090285879A1 (en) | 2009-11-19 |
| AU2005293572B2 (en) | 2011-08-04 |
| JP5108521B2 (ja) | 2012-12-26 |
| PL1802336T3 (pl) | 2012-03-30 |
| HK1100121A1 (en) | 2007-09-07 |
| EP1802336B1 (en) | 2011-09-07 |
| BRPI0518146A (pt) | 2008-10-28 |
| US20120014994A1 (en) | 2012-01-19 |
| WO2006040334A1 (en) | 2006-04-20 |
| RS52187B (en) | 2012-10-31 |
| AU2005293572A1 (en) | 2006-04-20 |
| ES2371175T3 (es) | 2011-12-28 |
| CY1112749T1 (el) | 2016-02-10 |
| MA29212B1 (fr) | 2008-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1802336T3 (da) | Malaria primer/boostervacciner | |
| DK1487485T3 (da) | Imidazoquinolinadjuvanser til DNA-vacciner | |
| CY1114584T1 (el) | Ανασυνδυασμενα εμβολια και χρηση αυτων | |
| ATE426412T1 (de) | Adjuvante influenza-vakzine | |
| WO2007008918A3 (en) | Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof | |
| EA200901060A1 (ru) | Новый способ и композиции | |
| WO2007027860A3 (en) | Adenoviral vector-based malaria vaccines | |
| SG156535A1 (en) | Recombinant viral-based malaria vaccines | |
| CY1110793T1 (el) | Εμβολιο φυματιωσης με βελτιωμενη αποτελεσματικοτητα | |
| WO2004080403A3 (en) | Influenza virus vaccine | |
| WO2004037189A3 (en) | Methods for vaccinating against malaria | |
| NO20062948L (no) | Promotere for ekspresjon i modifisert vaccinia-virus Ankara | |
| WO2003011331A3 (en) | Materials and methods relating to improved vaccination strategies | |
| MX2013003238A (es) | Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. | |
| NZ596223A (en) | Combined measles-malaria vaccine | |
| DK1962889T3 (da) | Immunogent polypeptid nestående af tumorantigenafledte optimerede kryptiske peptider samt anvendelser deraf | |
| WO2003093298A3 (en) | Immunogenic peptides | |
| WO2002092628A3 (fr) | Antigenes de plasmodium falciparum et leurs applications vaccinales et diagnostiques | |
| WO2007104263A8 (zh) | 一种乙型肝炎病毒疫苗增效蛋白及其基因 | |
| WO2008027414A3 (en) | Novel p. falciparum vaccine proteins and coding sequences | |
| DE602004028512D1 (de) | Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon | |
| DE60330256D1 (de) | Bakteriophagen-vermittelte immunisierung gegen hepatitis | |
| ATE535606T1 (de) | Rekombinanter virus-basierter malaria impfstoff | |
| TH78132A (th) | วัคซีน bcg และการใช้ประโยชน์ของมัน | |
| TH78132B (th) | วัคซีน bcg และการใช้ประโยชน์ของมัน |